Search

everythinglearnresearchcommunity

for

Search:↓

Certain immune system genes are linked to a higher risk of psoriasis and psoriatic arthritis, while others may offer protection.

Dermoscopy helped diagnose a rare skin disease which slightly improved with treatment.

Genetic marker rs12558842 strongly linked to male hair loss.

Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Eclipta prostrata, particularly its chloroform fraction, effectively reduces inflammation and arthritis.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

A risk prediction model can help diagnose systemic lupus erythematosus earlier in primary care.

VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.

Skin changes in Pseudoxanthoma elasticum patients can indicate the severity of related health issues.

Alitretinoin may help treat alopecia areata.

Early recognition and zinc treatment can effectively improve acrodermatitis symptoms.

The patient with Ankylosing Spondylitis had shoulder joint damage and bone changes.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

The HPTLC method is effective and accurate for measuring linoleic and oleanolic acid in Eclipta alba.

FCER1A and RGS1 may help diagnose and treat systemic lupus erythematosus.

The new cream is safe and effective for mild to moderate atopic dermatitis.

New criteria for diagnosing frontal fibrosing alopecia include specific scalp and eyebrow hair loss as major factors and other hair loss areas and hair analysis as minor factors.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

New treatments and understanding of skin lupus are emerging in 2024.

Chronic scarring alopecia is common in SLE patients and needs early detection and management.

Scalp lesions in discoid lupus are more common in women and linked to other autoimmune diseases.